

Boulevard, Room 5134, Bethesda, MD 20892, (301) 496-9223, [surojeet.sengupta@nih.gov](mailto:surojeet.sengupta@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Molecular and Cellular Topics in Basic Neuroscience.

*Date:* August 5-6, 2025.

*Time:* 9:30 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Ipolia R. Ramadan, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, National Institute on Drug Abuse, NIH, Bethesda, MD 20892, (301) 827-4471, [ramadanir@mail.nih.gov](mailto:ramadanir@mail.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Miniaturization and Automation of Tissue Chip Systems (MATCHS).

*Date:* August 5, 2025.

*Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Bruce Sundstrom, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room 3G11A, National Institutes of Health/ NIAID, 5601 Fishers Lane, MSC 9834, Bethesda, MD 20892-9834, (240) 669-5045, [sundstromj@niaid.nih.gov](mailto:sundstromj@niaid.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Career Development and Research Education Programs.

*Date:* August 5, 2025.

*Time:* 10:00 a.m. to 3:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Chee Lim, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4128, Bethesda, MD 20892, (301) 435-1850, [limc4@csr.nih.gov](mailto:limc4@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Fellowships: Endocrine and Metabolic Systems.

*Date:* August 6, 2025.

*Time:* 9:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Zhuqing Li, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room #3G41B, National Institutes of Health/ NIAID, 5601 Fishers Lane, MSC 9834, Bethesda, MD 20892-9834, (240) 669-5068, [zhuqing.li@nih.gov](mailto:zhuqing.li@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel;

Fellowships: Aging, Neurodegeneration, and Neurotoxicology.

*Date:* August 6-7, 2025.

*Time:* 9:30 a.m. to 8:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Rahat Rani Khan, Ph.D., Scientific Review Officer, Office of Grants Management and Scientific Review, National Center for Advancing Translational Sciences, 6701 Democracy Blvd., Rm. 1078, Bethesda, MD 20892, 301-594-7319, [Khanr2@mail.nih.gov](mailto:Khanr2@mail.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Molecular Genetics and Genomics

*Date:* August 6-7, 2025.

*Time:* 9:30 a.m. to 5:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Dharmendar Rathore, Ph.D., Chief, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute on Drug Abuse, NIH 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 402-6965, [dharmendar.rathore@nih.gov](mailto:dharmendar.rathore@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel Topics in Infectious Disease.

*Date:* August 6, 2025.

*Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Jennifer Hartt Meyers, Ph.D., Scientific Review Program, DEA/ NIAID/NIH/DHHS, 5601 Fishers Lane, MSC-9823, Rockville, MD 20852, 301-761-6602, [jennifer.meyers@nih.gov](mailto:jennifer.meyers@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: June 30, 2025.

**Bruce A. George,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2025-12378 Filed 7-1-25; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive, Inter-Institutional Agreement-Institution Lead: Generation of Antigen-Specific T and B Cells Using Engineered Commensals

**AGENCY:** National Institutes of Health, National Institute of Allergy and Infectious Diseases, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive, Inter-Institutional Agreement-Institution Lead to CZ Biohub SF, LLC ("CZB"), located in San Francisco, California, in its rights to the technologies and patent applications listed in the Supplementary Information section of this notice.

**DATES:** Only written comments and/or applications for a license which are received by the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, on or before July 17, 2025 will be considered.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive, Inter-Institutional Agreement-Institution Lead should be directed to: Jonathan Motley, Ph.D., Technology Transfer and Patent Specialist, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, 6D29, MSC9804, Rockville, MD 20852-9804, phone number 240-669-5209, or [jonathan.motley@nih.gov](mailto:jonathan.motley@nih.gov).

**SUPPLEMENTARY INFORMATION:** The following and all continuing U.S. patents/patent applications thereof are the intellectual properties to be licensed under the prospective agreement to CZB: United States Provisional Patent Application Serial No. 63/588,398, filed October 6, 2023, the title of which is "Generation Of Antigen-Specific T And B Cells Using Engineered Commensals" (HHS Reference No. E-047-2024-0-US-01); and PCT Application Number PCT/US24/50039, filed October 4, 2024 (HHS Reference No. E-047-2024-0-PC-01), the title of which is "Generation Of Antigen-Specific T And B Cells Using Engineered Commensals".

The patent rights to this technology have been assigned to CZB, The Board Of Trustees Of The Leland Stanford

Junior University, and the Government of the United States of America as represented by the Secretary, Department of Health & Human Services.

The prospective patent license will be for the purpose of consolidating the patent rights to CZB, for the development and commercialization of the technology.

Consolidation of these co-owned rights is intended to expedite development of the technology, consistent with the goals of the Bayh-Dole Act codified as 35 U.S.C. 200–212.

The prospective interinstitutional agreement may include an exclusive license for NIAID's rights in these jointly owned patents. It will be sublicensable, and any sublicenses granted by CZB will be subject to the provisions of 37 CFR part 404.

In the subject technology, the inventors describe a method of modifying commensal bacteria to carry heterologous antigenic fragments and the use of these modified bacterial cells to specifically stimulate or reduce a host's immune response by modulating the response of T- and B-cells or antigen-presenting cells (APCs). To modify the bacterial cells, the inventors describe the use of genetic tools and fusion proteins, transpeptidases, or by using covalent bonding of the antigenic fragment to extracellular proteins found on the surface. The modified bacteria are then applied to the skin or mucosal membranes of a target mammal (including humans). Other applications could include the delivery of molecules encased in lipid nanoparticles by adhering them to the surface of the commensal bacteria via the modification methods described above.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice the National Institute of Allergy and Infectious Diseases receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

Complete license applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as

required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: June 30, 2025.

**Surekha Vathyam,**

*Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.*

[FR Doc. 2025–12381 Filed 7–1–25; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

#### FOR FURTHER INFORMATION CONTACT:

Brian Bailey at 240–669–5128, or [bbailey@mail.nih.gov](mailto:bbailey@mail.nih.gov). Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

#### SUPPLEMENTARY INFORMATION:

Technology description follows:

#### EV–D68 Monoclonal Antibodies Isolated From Immunized Rhesus Macaques

##### Description of Technology:

Enterovirus D68 (EV–D68) has been linked to the widespread outbreaks of respiratory illness and acute flaccid myelitis (AFM) in the United States and Europe in 2014, 2016, and 2018. Although EV–D68 is now the most frequently encountered enterovirus (41.1% of cases), with an estimated global prevalence of 4%, there are no specific, FDA-approved therapeutic interventions targeting this virus.

Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Disease (NIAID)

have identified four monoclonal antibodies that potently bind and neutralize multiple subclades of EV–D68, including B3 and A2 variants. Animal studies have indicated that these Rhesus macaque-derived monoclonal antibodies (mAbs) are likely to confer protection against respiratory illness in young children (particularly those under age 5) and in individuals with respiratory or immunocompromising conditions. Analyses conducted using standard techniques such as cryo-EM have enabled the inventors to further characterize the epitopes of two unique EV–D68-specific antibodies, suggesting the value of this technology for developing multi-specific approaches that confer broad protection against EV–D68.

Humanization and combination of these mAbs with other antibodies exhibiting unique epitope specificities may prove beneficial for therapeutic or prophylactic purposes, especially within the context of a broader pandemic preparedness program. Further, these antibodies could be incorporated into diagnostic assays/kits for the rapid and accurate detection of EV–D68 in clinical or non-clinical settings.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

#### Potential Commercial Applications:

- Prevention or treatment of EV–D68 infection
- Development of diagnostic assays for rapid, accurate EV–D68 detection in clinical and non-clinical settings

#### Competitive Advantages:

- Development of prophylactic or therapeutic interventions against EV–D68 that effectively induce broad protection against multiple circulating subclades

#### Development Stage: Preclinical

**Inventors:** Tracy Ruckwardt, Daniel Moss, Peter Krug, Masaru Kanekiyo (all of NIAID VRC)

**Relevant Publications:** Krug et al. EV–D68 virus-like particle vaccines elicit cross-clade neutralizing antibodies that inhibit infection and block dissemination. *Sci. Adv.* 2023;9:eadg6076. DOI:10.1126/sciadv.adg6076

**Intellectual Property:** HHS Reference No. E–041–2024; Provisional Patent Application 63/640,619, filed on April 30, 2024, and PCT Patent Application No. PCT/US2025/027110, filed on April 30, 2025.

**Licensing Contact:** To license this technology, please contact Brian Bailey